BioPorto Diagnostics A/S (CPH:BIOPOR) shares have almost doubled in value in little over a month, reflecting the progress it has made with its ten-minute COVID-19 test.
This potentially ground-breaking technology is being developed in harness with the University of Southern Denmark, which brings to the party its antibody expertise.
If successful, the company intends to file for fast-track emergency use in the US along and is pursuing official sign-off for the device in Europe too.
All of this means BioPorto could have its ten-minute test out on the market by the end of the year.
Chief medical officer Christopher Bird will explain all when he presents to the Proactive Virtual Forum on Tuesday October 27, from 1pm EST.
About the event:
- Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts
- We look beyond the numbers and meet the people creating the value for shareholders
- Each company has a presentation slot followed by Q & A, giving you the chance to discover the real story
- You can watch the event afterwards on our YouTube channel